Keywords: Bristol-Myers Squibb, Baraclude, Hepatitis B, Liver transplant, European Commission, Label change

EU approves label change for Bristol-Myer's Baraclude

Article | 06 November 2012

Print This

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the European Commission has approved a Baraclude (entecavir) Summary of Product ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in